Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
This report elaborates on the current development of the Targeted Drugs for Multiple Myeloma industry thoroughly based on the international market dynamics and China's market situation.
For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.
Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market.
Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.
By Player:
Celgene
PDL BioPharma
Amgen
Abbvie
Schering-Plough
Chiron
Seattle Genetics
Chia Tai-Tianqing
Roche
Takeda
Shandong Kongfu Pharmaceutical
SL Pharma
Biogen
Intas Pharmaceuticals
J&J
Glenmark Pharmaceuticals
Merck
Cipla
Sumitomo
Indiabulls Pharmaceutical
Bristol Myers Squibb
Dr Reddy's Laboratories
Glaxo
Natco Pharma
Karyopharm Therapeutics
By Type:
Other
Monoclonal Antibody
Histone Deacetylase Inhibitors (HDACI)
Proteasome Inhibitors
Immunomodulator
By Application:
Hospital
Clinic
Other
Drug Center
By Research Region:
-
North China
-
Central China
-
South China
-
East China
-
Northeast China
-
Southwest China
-
Northwest China
TABLE OF CONTENT
Chapter 1 China Targeted Drugs for Multiple Myeloma Market Overview 2018-2029
-
1.1 China Targeted Drugs for Multiple Myeloma Industry Development Overview
-
1.2 China Targeted Drugs for Multiple Myeloma Industry Development History
-
1.3 China Targeted Drugs for Multiple Myeloma Industry Market Size (2018-2029)
-
1.4 China Targeted Drugs for Multiple Myeloma Market Analysis by Type from Production Side
-
1.4.1 China Targeted Drugs for Multiple Myeloma Production Volume, Production Value and Growth Rate of Other (2018-2029)
-
1.4.2 China Targeted Drugs for Multiple Myeloma Production Volume, Production Value and Growth Rate of Monoclonal Antibody (2018-2029)
-
1.4.3 China Targeted Drugs for Multiple Myeloma Production Volume, Production Value and Growth Rate of Histone Deacetylase Inhibitors (HDACI) (2018-2029)
-
1.4.4 China Targeted Drugs for Multiple Myeloma Production Volume, Production Value and Growth Rate of Proteasome Inhibitors (2018-2029)
-
1.4.5 China Targeted Drugs for Multiple Myeloma Production Volume, Production Value and Growth Rate of Immunomodulator (2018-2029)
-
1.5 China Targeted Drugs for Multiple Myeloma Market Analysis by Application from Consumption End
-
1.5.1 China Targeted Drugs for Multiple Myeloma Sales Volume, Sales Value and Growth Rate of Hospital (2018-2029)
-
1.5.2 China Targeted Drugs for Multiple Myeloma Sales Volume, Sales Value and Growth Rate of Clinic (2018-2029)
-
1.5.3 China Targeted Drugs for Multiple Myeloma Sales Volume, Sales Value and Growth Rate of Other (2018-2029)
-
1.5.4 China Targeted Drugs for Multiple Myeloma Sales Volume, Sales Value and Growth Rate of Drug Center (2018-2029)
-
1.6 China Targeted Drugs for Multiple Myeloma Market Analysis by Region
-
1.6.1 North China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate from 2018-2029
-
1.6.2 Central China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate from 2018-2029
-
1.6.3 South China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate from 2018-2029
-
1.6.4 East China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate from 2018-2029
-
1.6.5 Northeast China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate from 2018-2029
-
1.6.6 Southwest China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate from 2018-2029
-
1.6.7 Northwest China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate from 2018-2029
Chapter 2 China Targeted Drugs for Multiple Myeloma Industry Development Environment
-
2.1 Industry Development Environment Analysis
-
2.1.1 Industry Technological Progress Analysis
-
2.1.2 Industrial Organizational Innovation Analysis
-
2.1.3 Changes in Social Habits
-
2.1.4 Alterations in Government Policies
-
2.1.5 Impact of Economic Globalization
-
2.2 Domestic and Foreign Industry Competition Analysis
-
2.2.1 Comparative Analysis on Targeted Drugs for Multiple Myeloma Market Status and Competition at home and abroad in 2023
-
2.2.2 China Targeted Drugs for Multiple Myeloma Market Status and Competition Analysis in 2023
-
2.2.3 China Targeted Drugs for Multiple Myeloma Market Concentration Analysis in 2023
-
2.3 Problems and Countermeasures in the development of China Targeted Drugs for Multiple Myeloma Industry
-
2.3.1 Industry Development Constraints
-
2.3.2 Industry Development Considerations
-
2.3.3 Suggestions on Industry Development Measures
-
2.3.4 Development Strategies for SMEs
-
2.4 Influence of COVID-19 Outbreak on Targeted Drugs for Multiple Myeloma Industry Development
Chapter 3 Targeted Drugs for Multiple MyelomaIndustry Chain Analysis
-
3.1 Targeted Drugs for Multiple Myeloma Industry Chain
-
3.2 Targeted Drugs for Multiple Myeloma Upstream Industry Analysis
-
3.2.1 Upstream Industry Development Status
-
3.2.2 Upstream Industry Development Forecast
-
3.2.3 Impact of Upstream Industry on the Targeted Drugs for Multiple Myeloma Market
-
3.3 Targeted Drugs for Multiple Myeloma Downstream Industry Analysis
-
3.3.1 Downstream Industry Development Status
-
3.3.2 Downstream Industry Development Forecast
-
3.3.3 Impact of Downstream Industry on the Targeted Drugs for Multiple Myeloma Market
Chapter 4 China Targeted Drugs for Multiple Myeloma Market, by Type
-
4.1 China Targeted Drugs for Multiple Myeloma Market Trend, by Type
-
4.2 Product Types of Major Suppliers
-
4.3 Competitive Landscape of Major Types
-
4.4 China Targeted Drugs for Multiple Myeloma Total Production Volume and Growth Rate from Production Side
-
4.5 China Targeted Drugs for Multiple Myeloma Production Volume and Growth Rate, by Type
-
4.5.1 China Targeted Drugs for Multiple Myeloma Production Volume and Growth Rate of Other
-
4.5.2 China Targeted Drugs for Multiple Myeloma Production Volume and Growth Rate of Monoclonal Antibody
-
4.5.3 China Targeted Drugs for Multiple Myeloma Production Volume and Growth Rate of Histone Deacetylase Inhibitors (HDACI)
-
4.5.4 China Targeted Drugs for Multiple Myeloma Production Volume and Growth Rate of Proteasome Inhibitors
-
4.5.5 China Targeted Drugs for Multiple Myeloma Production Volume and Growth Rate of Immunomodulator
Chapter 5 China Targeted Drugs for Multiple Myeloma Market, by Application
-
5.1 Downstream Market Overview
-
5.2 Competitive Landscape of Major Applications
-
5.3 Market Potential Analysis, by Application
-
5.4 China Targeted Drugs for Multiple Myeloma Total Market Size and Growth Rate from Consumption End
-
5.5 China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate, by Application
-
5.5.1 China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate of Hospital
-
5.5.2 China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate of Clinic
-
5.5.3 China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate of Other
-
5.5.4 China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate of Drug Center
Chapter 6 China Targeted Drugs for Multiple Myeloma Market, by Region
-
6.1 China Targeted Drugs for Multiple Myeloma Production Volume and Production Value, by Region
-
6.2 China Targeted Drugs for Multiple Myeloma Sales Volume and Sales Value, by Region
Chapter 7 North China Targeted Drugs for Multiple Myeloma Market Analysis
-
7.1 North China Targeted Drugs for Multiple Myeloma Market, by Type
-
7.2 North China Targeted Drugs for Multiple Myeloma Market, by Application
Chapter 8 Central China Targeted Drugs for Multiple Myeloma Market Analysis
-
8.1 Central China Targeted Drugs for Multiple Myeloma Market, by Type
-
8.2 Central China Targeted Drugs for Multiple Myeloma Market, by Application
Chapter 9 South China Targeted Drugs for Multiple Myeloma Market Analysis
-
9.1 South China Targeted Drugs for Multiple Myeloma Market, by Type
-
9.2 South China Targeted Drugs for Multiple Myeloma Market, by Application
Chapter 10 East China Targeted Drugs for Multiple Myeloma Market Analysis
-
10.1 East China Targeted Drugs for Multiple Myeloma Market, by Type
-
10.2 East China Targeted Drugs for Multiple Myeloma Market, by Application
Chapter 11 Northeast China Targeted Drugs for Multiple Myeloma Market Analysis
-
11.1 Northeast China Targeted Drugs for Multiple Myeloma Market, by Type
-
11.2 Northeast China Targeted Drugs for Multiple Myeloma Market, by Application
Chapter 12 Southwest China Targeted Drugs for Multiple Myeloma Market Analysis
-
12.1 Southwest China Targeted Drugs for Multiple Myeloma Market, by Type
-
12.2 Southwest China Targeted Drugs for Multiple Myeloma Market, by Application
Chapter 13 Northwest China Targeted Drugs for Multiple Myeloma Market Analysis
-
13.1 Northwest China Targeted Drugs for Multiple Myeloma Market, by Type
-
13.2 Northwest China Targeted Drugs for Multiple Myeloma Market, by Application
Chapter 14 Company Profiles
-
14.1 Celgene
-
14.1.1 Celgene Company Profile
-
14.1.2 Celgene Targeted Drugs for Multiple Myeloma Market Performance
-
14.1.3 Product&Service Introduction
-
14.2 PDL BioPharma
-
14.2.1 PDL BioPharma Company Profile
-
14.2.2 PDL BioPharma Targeted Drugs for Multiple Myeloma Market Performance
-
14.2.3 Product&Service Introduction
-
14.3 Amgen
-
14.3.1 Amgen Company Profile
-
14.3.2 Amgen Targeted Drugs for Multiple Myeloma Market Performance
-
14.3.3 Product&Service Introduction
-
14.4 Abbvie
-
14.4.1 Abbvie Company Profile
-
14.4.2 Abbvie Targeted Drugs for Multiple Myeloma Market Performance
-
14.4.3 Product&Service Introduction
-
14.5 Schering-Plough
-
14.5.1 Schering-Plough Company Profile
-
14.5.2 Schering-Plough Targeted Drugs for Multiple Myeloma Market Performance
-
14.5.3 Product&Service Introduction
-
14.6 Chiron
-
14.6.1 Chiron Company Profile
-
14.6.2 Chiron Targeted Drugs for Multiple Myeloma Market Performance
-
14.6.3 Product&Service Introduction
-
14.7 Seattle Genetics
-
14.7.1 Seattle Genetics Company Profile
-
14.7.2 Seattle Genetics Targeted Drugs for Multiple Myeloma Market Performance
-
14.7.3 Product&Service Introduction
-
14.8 Chia Tai-Tianqing
-
14.8.1 Chia Tai-Tianqing Company Profile
-
14.8.2 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Market Performance
-
14.8.3 Product&Service Introduction
-
14.9 Roche
-
14.9.1 Roche Company Profile
-
14.9.2 Roche Targeted Drugs for Multiple Myeloma Market Performance
-
14.9.3 Product&Service Introduction
-
14.10 Takeda
-
14.10.1 Takeda Company Profile
-
14.10.2 Takeda Targeted Drugs for Multiple Myeloma Market Performance
-
14.10.3 Product&Service Introduction
-
14.11 Shandong Kongfu Pharmaceutical
-
14.11.1 Shandong Kongfu Pharmaceutical Company Profile
-
14.11.2 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Market Performance
-
14.11.3 Product&Service Introduction
-
14.12 SL Pharma
-
14.12.1 SL Pharma Company Profile
-
14.12.2 SL Pharma Targeted Drugs for Multiple Myeloma Market Performance
-
14.12.3 Product&Service Introduction
-
14.13 Biogen
-
14.13.1 Biogen Company Profile
-
14.13.2 Biogen Targeted Drugs for Multiple Myeloma Market Performance
-
14.13.3 Product&Service Introduction
-
14.14 Intas Pharmaceuticals
-
14.14.1 Intas Pharmaceuticals Company Profile
-
14.14.2 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Market Performance
-
14.14.3 Product&Service Introduction
-
14.15 J&J
-
14.15.1 J&J Company Profile
-
14.15.2 J&J Targeted Drugs for Multiple Myeloma Market Performance
-
14.15.3 Product&Service Introduction
-
14.16 Glenmark Pharmaceuticals
-
14.16.1 Glenmark Pharmaceuticals Company Profile
-
14.16.2 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Market Performance
-
14.16.3 Product&Service Introduction
-
14.17 Merck
-
14.17.1 Merck Company Profile
-
14.17.2 Merck Targeted Drugs for Multiple Myeloma Market Performance
-
14.17.3 Product&Service Introduction
-
14.18 Cipla
-
14.18.1 Cipla Company Profile
-
14.18.2 Cipla Targeted Drugs for Multiple Myeloma Market Performance
-
14.18.3 Product&Service Introduction
-
14.19 Sumitomo
-
14.19.1 Sumitomo Company Profile
-
14.19.2 Sumitomo Targeted Drugs for Multiple Myeloma Market Performance
-
14.19.3 Product&Service Introduction
-
14.20 Indiabulls Pharmaceutical
-
14.20.1 Indiabulls Pharmaceutical Company Profile
-
14.20.2 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Market Performance
-
14.20.3 Product&Service Introduction
-
14.21 Bristol Myers Squibb
-
14.21.1 Bristol Myers Squibb Company Profile
-
14.21.2 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Market Performance
-
14.21.3 Product&Service Introduction
-
14.22 Dr Reddy's Laboratories
-
14.22.1 Dr Reddy's Laboratories Company Profile
-
14.22.2 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Market Performance
-
14.22.3 Product&Service Introduction
-
14.23 Glaxo
-
14.23.1 Glaxo Company Profile
-
14.23.2 Glaxo Targeted Drugs for Multiple Myeloma Market Performance
-
14.23.3 Product&Service Introduction
-
14.24 Natco Pharma
-
14.24.1 Natco Pharma Company Profile
-
14.24.2 Natco Pharma Targeted Drugs for Multiple Myeloma Market Performance
-
14.24.3 Product&Service Introduction
-
14.25 Karyopharm Therapeutics
-
14.25.1 Karyopharm Therapeutics Company Profile
-
14.25.2 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Market Performance
-
14.25.3 Product&Service Introduction
Chapter 15 Research Conclusions and Investment Suggestions
-
15.1 Targeted Drugs for Multiple Myeloma Industry Research Conclusions
-
15.2 Targeted Drugs for Multiple Myeloma Industry Investment Suggestions
-
15.2.1 Suggestions on Industry Development Strategy
-
15.2.2 Suggestions on Industry Investment Direction
-
15.2.3 Suggestions on Industry Investment Strategy
List of Tables and Figures
-
Figure China Targeted Drugs for Multiple Myeloma Industry Market Size (2018-2029)
-
Figure China Targeted Drugs for Multiple Myeloma Production Volume, Production Value and Growth Rate of Other (2018-2029)
-
Figure China Targeted Drugs for Multiple Myeloma Production Volume, Production Value and Growth Rate of Monoclonal Antibody (2018-2029)
-
Figure China Targeted Drugs for Multiple Myeloma Production Volume, Production Value and Growth Rate of Histone Deacetylase Inhibitors (HDACI) (2018-2029)
-
Figure China Targeted Drugs for Multiple Myeloma Production Volume, Production Value and Growth Rate of Proteasome Inhibitors (2018-2029)
-
Figure China Targeted Drugs for Multiple Myeloma Production Volume, Production Value and Growth Rate of Immunomodulator (2018-2029)
-
Figure China Targeted Drugs for Multiple Myeloma Sales Volume, Sales Value and Growth Rate of Hospital (2018-2029)
-
Figure China Targeted Drugs for Multiple Myeloma Sales Volume, Sales Value and Growth Rate of Clinic (2018-2029)
-
Figure China Targeted Drugs for Multiple Myeloma Sales Volume, Sales Value and Growth Rate of Other (2018-2029)
-
Figure China Targeted Drugs for Multiple Myeloma Sales Volume, Sales Value and Growth Rate of Drug Center (2018-2029)
-
Figure North China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate from 2018-2029
-
Figure Central China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate from 2018-2029
-
Figure South China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate from 2018-2029
-
Figure East China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate from 2018-2029
-
Figure Northeast China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate from 2018-2029
-
Figure Southwest China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate from 2018-2029
-
Figure Northwest China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate from 2018-2029
-
Figure Targeted Drugs for Multiple Myeloma Industry Chain
-
Table Product Types of Major Suppliers in 2023
-
Figure China Targeted Drugs for Multiple Myeloma Market Share by Type in 2018
-
Figure China Targeted Drugs for Multiple Myeloma Market Share by Type in 2023
-
Figure China Targeted Drugs for Multiple Myeloma Total Production Volume and Growth Rate from Production Side (2018-2023)
-
Figure China Targeted Drugs for Multiple Myeloma Production Volume and Growth Rate of Other (2018-2023)
-
Figure China Targeted Drugs for Multiple Myeloma Production Volume and Growth Rate of Monoclonal Antibody (2018-2023)
-
Figure China Targeted Drugs for Multiple Myeloma Production Volume and Growth Rate of Histone Deacetylase Inhibitors (HDACI) (2018-2023)
-
Figure China Targeted Drugs for Multiple Myeloma Production Volume and Growth Rate of Proteasome Inhibitors (2018-2023)
-
Figure China Targeted Drugs for Multiple Myeloma Production Volume and Growth Rate of Immunomodulator (2018-2023)
-
Figure China Targeted Drugs for Multiple Myeloma Market Share by Application in 2018
-
Figure China Targeted Drugs for Multiple Myeloma Market Share by Application in 2023
-
Figure China Targeted Drugs for Multiple Myeloma Total Market Size and Growth Rate from Consumption End
-
Figure China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate of Hospital (2018-2023)
-
Figure China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate of Clinic (2018-2023)
-
Figure China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate of Other (2018-2023)
-
Figure China Targeted Drugs for Multiple Myeloma Market Size and Growth Rate of Drug Center (2018-2023)
-
Table China Targeted Drugs for Multiple Myeloma Production Volume by Region (2018-2023)
-
Table China Targeted Drugs for Multiple Myeloma Production Volume Share by Region (2018-2023)
-
Figure China Targeted Drugs for Multiple Myeloma Production Volume Share by Region (2018-2023)
-
Table China Targeted Drugs for Multiple Myeloma Production Value by Region (2018-2023)
-
Table China Targeted Drugs for Multiple Myeloma Production Value Share by Region (2018-2023)
-
Figure China Targeted Drugs for Multiple Myeloma Production Value Share by Region (2018-2023)
-
Table China Targeted Drugs for Multiple Myeloma Sales Volume by Region (2018-2023)
-
Table China Targeted Drugs for Multiple Myeloma Sales Volume Share by Region (2018-2023)
-
Figure China Targeted Drugs for Multiple Myeloma Sales Volume Share by Region (2018-2023)
-
Table China Targeted Drugs for Multiple Myeloma Sales Value by Region (2018-2023)
-
Table China Targeted Drugs for Multiple Myeloma Sales Value Share by Region (2018-2023)
-
Figure China Targeted Drugs for Multiple Myeloma Sales Value Share by Region (2018-2023)
-
Table North China Targeted Drugs for Multiple Myeloma Production Volume by Type (2018-2023)
-
Table North China Targeted Drugs for Multiple Myeloma Production Volume Share by Type (2018-2023)
-
Figure North China Targeted Drugs for Multiple Myeloma Production Volume Share by Type (2018-2023)
-
Table North China Targeted Drugs for Multiple Myeloma Sales Volume by Application (2018-2023)
-
Table North China Targeted Drugs for Multiple Myeloma Sales Volume Share by Application (2018-2023)
-
Figure North China Targeted Drugs for Multiple Myeloma Sales Volume Share by Application (2018-2023)
-
Table Central China Targeted Drugs for Multiple Myeloma Production Volume by Type (2018-2023)
-
Table Central China Targeted Drugs for Multiple Myeloma Production Volume Share by Type (2018-2023)
-
Figure Central China Targeted Drugs for Multiple Myeloma Production Volume Share by Type (2018-2023)
-
Table Central China Targeted Drugs for Multiple Myeloma Sales Volume by Application (2018-2023)
-
Table Central China Targeted Drugs for Multiple Myeloma Sales Volume Share by Application (2018-2023)
-
Figure Central China Targeted Drugs for Multiple Myeloma Sales Volume Share by Application (2018-2023)
-
Table South China Targeted Drugs for Multiple Myeloma Production Volume by Type (2018-2023)
-
Table South China Targeted Drugs for Multiple Myeloma Production Volume Share by Type (2018-2023)
-
Figure South China Targeted Drugs for Multiple Myeloma Production Volume Share by Type (2018-2023)
-
Table South China Targeted Drugs for Multiple Myeloma Sales Volume by Application (2018-2023)
-
Table South China Targeted Drugs for Multiple Myeloma Sales Volume Share by Application (2018-2023)
-
Figure South China Targeted Drugs for Multiple Myeloma Sales Volume Share by Application (2018-2023)
-
Table East China Targeted Drugs for Multiple Myeloma Production Volume by Type (2018-2023)
-
Table East China Targeted Drugs for Multiple Myeloma Production Volume Share by Type (2018-2023)
-
Figure East China Targeted Drugs for Multiple Myeloma Production Volume Share by Type (2018-2023)
-
Table East China Targeted Drugs for Multiple Myeloma Sales Volume by Application (2018-2023)
-
Table East China Targeted Drugs for Multiple Myeloma Sales Volume Share by Application (2018-2023)
-
Figure East China Targeted Drugs for Multiple Myeloma Sales Volume Share by Application (2018-2023)
-
Table Northeast China Targeted Drugs for Multiple Myeloma Production Volume by Type (2018-2023)
-
Table Northeast China Targeted Drugs for Multiple Myeloma Production Volume Share by Type (2018-2023)
-
Figure Northeast China Targeted Drugs for Multiple Myeloma Production Volume Share by Type (2018-2023)
-
Table Northeast China Targeted Drugs for Multiple Myeloma Sales Volume by Application (2018-2023)
-
Table Northeast China Targeted Drugs for Multiple Myeloma Sales Volume Share by Application (2018-2023)
-
Figure Northeast China Targeted Drugs for Multiple Myeloma Sales Volume Share by Application (2018-2023)
-
Table Southwest China Targeted Drugs for Multiple Myeloma Production Volume by Type (2018-2023)
-
Table Southwest China Targeted Drugs for Multiple Myeloma Production Volume Share by Type (2018-2023)
-
Figure Southwest China Targeted Drugs for Multiple Myeloma Production Volume Share by Type (2018-2023)
-
Table Southwest China Targeted Drugs for Multiple Myeloma Sales Volume by Application (2018-2023)
-
Table Southwest China Targeted Drugs for Multiple Myeloma Sales Volume Share by Application (2018-2023)
-
Figure Southwest China Targeted Drugs for Multiple Myeloma Sales Volume Share by Application (2018-2023)
-
Table Northwest China Targeted Drugs for Multiple Myeloma Production Volume by Type (2018-2023)
-
Table Northwest China Targeted Drugs for Multiple Myeloma Production Volume Share by Type (2018-2023)
-
Figure Northwest China Targeted Drugs for Multiple Myeloma Production Volume Share by Type (2018-2023)
-
Table Northwest China Targeted Drugs for Multiple Myeloma Sales Volume by Application (2018-2023)
-
Table Northwest China Targeted Drugs for Multiple Myeloma Sales Volume Share by Application (2018-2023)
-
Figure Northwest China Targeted Drugs for Multiple Myeloma Sales Volume Share by Application (2018-2023)
-
Table Celgene Company Profile
-
Table Celgene Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table PDL BioPharma Company Profile
-
Table PDL BioPharma Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table Amgen Company Profile
-
Table Amgen Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table Abbvie Company Profile
-
Table Abbvie Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table Schering-Plough Company Profile
-
Table Schering-Plough Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table Chiron Company Profile
-
Table Chiron Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table Seattle Genetics Company Profile
-
Table Seattle Genetics Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table Chia Tai-Tianqing Company Profile
-
Table Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table Roche Company Profile
-
Table Roche Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table Takeda Company Profile
-
Table Takeda Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table Shandong Kongfu Pharmaceutical Company Profile
-
Table Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table SL Pharma Company Profile
-
Table SL Pharma Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table Biogen Company Profile
-
Table Biogen Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table Intas Pharmaceuticals Company Profile
-
Table Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table J&J Company Profile
-
Table J&J Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table Glenmark Pharmaceuticals Company Profile
-
Table Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table Merck Company Profile
-
Table Merck Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table Cipla Company Profile
-
Table Cipla Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table Sumitomo Company Profile
-
Table Sumitomo Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table Indiabulls Pharmaceutical Company Profile
-
Table Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table Bristol Myers Squibb Company Profile
-
Table Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table Dr Reddy's Laboratories Company Profile
-
Table Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table Glaxo Company Profile
-
Table Glaxo Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table Natco Pharma Company Profile
-
Table Natco Pharma Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
Table Karyopharm Therapeutics Company Profile
-
Table Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Revenue, Price and Gross (2018-2023)
-
